Akero Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Janus Henderson Group plc has filed an amendment to its Schedule 13G, reporting a reduced beneficial ownership of 4.1% in Akero Therapeutics, Inc.
RTW Investments and Roderick Wong have fully divested their beneficial ownership in Akero Therapeutics, Inc., now holding 0.0% of common stock.
Deep Track Capital and its affiliates have reported a 0% beneficial ownership in Akero Therapeutics, Inc., indicating a full divestment or reduction below the reporting threshold.
Wellington Management Group and its affiliates have reported a 0.0% beneficial ownership in Akero Therapeutics, Inc. common stock, indicating a full divestment.
T. Rowe Price Associates, Inc. reported a 4.8% beneficial ownership in Akero Therapeutics Inc., indicating a position below the 5% threshold.
Janus Henderson Group plc has increased its beneficial ownership in Akero Therapeutics, Inc. to 7.9% of ordinary shares, as disclosed in an amended Schedule 13G filing.
Wellington Management Group LLP and its affiliates have reported a 5.3% beneficial ownership stake in Akero Therapeutics, Inc. common stock as of September 30, 2025.
Deep Track Capital, LP and its affiliates have reported a passive 5.5% ownership stake in Akero Therapeutics, Inc., holding 4.4 million shares.
Janus Henderson Group plc has filed an amended Schedule 13G, reporting a beneficial ownership of 8.4% in Akero Therapeutics, Inc.'s Ordinary Shares.
RTW Investments and Roderick Wong report a 7.3% passive beneficial ownership stake in Akero Therapeutics, Inc., holding 5,873,308 shares.
Wellington Management Group and its affiliates reported a 4.28% beneficial ownership stake in Akero Therapeutics, Inc. as of June 30, 2025, in its latest Schedule 13G amendment.
General Atlantic, along with its affiliated entities, has filed an amended Schedule 13G, revealing a collective beneficial ownership of 8.4% in Akero Therapeutics, Inc. common stock as of March 31, 2025.
SCHEDULE 13G/A: Janus Henderson Group Maintains Significant Passive Stake in Akero Therapeutics, Discloses 8.9% Ownership
Janus Henderson Group PLC has filed an Amendment No. 9 to its Schedule 13G, reaffirming its passive beneficial ownership of 8.9% of Akero Therapeutics, Inc.'s Ordinary Shares as of March 31, 2025.
Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, disclosing a beneficial ownership of 7.46% in Akero Therapeutics, Inc. common stock as of March 31, 2025.
Janus Henderson Group plc has filed an Amendment No. 8 to Schedule 13G, disclosing its beneficial ownership of 8.7% of Akero Therapeutics Inc's common stock as of December 31, 2024.
RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have filed an amended Schedule 13G, reporting a beneficial ownership of 9.8% in Akero Therapeutics, Inc. as of December 31, 2024.